The king of whole food antioxidants
- A natural fruit extract providing nutrient support for the heart
- Helps reduce cholesterol and regulate blood sugar levels
- Anti-inflammatory and antacid
- Provides a high dose of active tannins for maximum benefit
$37.44 — or subscribe and save 20%
Amla is an extract of Emblica officinalis, a fruit that is used in Ayurvedic medicine for a multitude of purposes. Its primary Ayurvedic function is as a rasayana, or an anti-aging compound. The amla fruit is packed with nutrients such as minerals, amino acids, polyphenols, antioxidants and essential fatty acids which collectively give it its anti-aging abilities. Moreover, amla extracts have been shown to have more powerful antioxidant activity than vitamin C because of their polyphenol content.
Due to their powerful antioxidant activity, amla extracts protect cholesterol against free-radical damage. Clinical trials have shown it to significantly improve the cholesterol profile, lowering LDL and total cholesterol and raising HDL. It may even help reduce blood sugar, making amla a powerful agent for cardiovascular support. Finally, amla has been traditionally used to fight chronic lung infections, upper respiratory infections and other types of infections. Those searching for powerful antioxidant support from an herb that has widespread health benefits or those looking for natural cholesterol support and anti-aging benefits would benefit from taking Amla.
AOR’s AMLA provides a very high dose of this supplement according to traditional Ayurvedic formulations, using only wild crafted (pesticide-free), culinary-grade amla extract, for a safe whole-food source of antioxidants.
Amla is an extract of Emblica officinalis, an Ayurvedic fruit shown to help prevent lipid peroxidation. Amla is the king of whole food antioxidants, boasting more antioxidant power than any other intact whole food.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal by product.
Take one capsule three times daily with/without food, or as directed by a qualified health care practitioner.
Do not use if pregnant or breastfeeding.
- Antiviral (colds/flu)
- Cardiovascular disease
- Bones, skin, collagen
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Non-medicinal Ingredients: sodium benzoate. Capsule: hypromellose.
In this randomized, double-blind, placebo-controlled, multicenter clinical trial, the efficacy (and safety) of Amla was assessed in patients with dyslipidemia, a common risk factor for atherosclerosis. 98 patients with dyslipidemia were randomized to receive either placebo or amla (500 mg) twice daily for 12 weeks. Each participant was assessed by analyzing lipid profiles, apolipoprotein A1, B, Coenzyme Q10 levels, C-reactive protein, fasting blood sugar, homocysteine levels, and thyroid-stimulating hormone levels.
Following 12 weeks of supplementation, there was a significant decrease in total cholesterol, triglycerides, LDL-cholesterol, and VLDL cholesterol levels in the amla supplementation group, compared to the placebo group. Additionally, a 39% reduction in the atherogenic index of the plasma (AIP) was also noted in the amla group. There was also a trend towards a reduction in fasting blood glucose, suggesting the potential of Amla as a hypoglycemic agent as well.
This systematic review of clinical trials evaluating the effect of Amla on cardiovascular pharmacology was published in 2018. It included 19 cell culture, animal and human clinical studies with the terms “antioxidant, arrhythmia, cardioprotective, cardiotoxicity, heart disease, heart failure, hyperlipidemia, hypertension, myocardial dysfunction, and oxidative stress”. The analysis of these studies show that Amla possesses antiatherogenic, anticoagulant, hypolipidemic, antihypertensive, antioxidant, antiplatelet, and vasodilatory effects as well as lipid deposition inhibitory properties. Additionally, it prevents from doxorubicin and isoproterenol cardiotoxicity and myocardial ischemia/reperfusion injury, and improves vascular endothelial function in animal studies, providing a reason to evaluate these effects in high-quality human studies. The authors summarize that Amla influences multiple risk factors for cardiovascular diseases.
The role of endothelial dysfunction in individuals with metabolic syndrome and atherosclerosis can’t be discounted. This randomised, double-blind, placebo-controlled clinical study aimed t evaluate the effect of Amla on endothelial dysfunction and corresponding biomarkers of oxidative stress, systemic inflammation and lipid profiles in patients with metabolic syndrome. Participants were randomized into one of three groups: group one – placebo; group two – 250 mg Amla twice daily; group three – 500 mg Amla twice daily for 12 weeks.
Results show a significant increase in nitric oxide, glutathione, and malonaldehyde levels, as markers of reduction in oxidative stress. Additionally, a significant reduction in C-reactive protein, as a marker of systemic inflammation was observed with both Amla doses at the 12-week mark. A significant reduction in total cholesterol and triglycerides was also observed, confirming results from previous reports that show that Amla significantly improves endothelial function, markers of oxidative stress and inflammation, and lipid profiles in humans, especially ones trending towards cardiovascular diseases.
This comparative, randomized clinical study aimed to evaluate the effect of Amla, in comparison to a 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor, simvastatin in patients with type II hyperlipidemia. Patients were randomized to receive simvastatin (20 mg/day) or Amla (500 mg/day) for 42 days. Blood samples were analyzed for various biochemical parameters and the values of Total Cholesterol (TC), Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), and Very Low-Density Lipoprotein (VLDL) were measured before and after completion of the treatment with Amla and simvastatin.
The results show a significant reduction in TC, LDL, triglycerides, and VLDL, with a corresponding increase in HDL levels from the baseline. This effect was comparable to what was observed in the simvastatin group. Both groups also showed a significant reduction in blood pressure, however, it was noted that the participants in the Amla group experienced a more significant reduction in blood pressure.
This in-vitro study evaluated the antioxidant effect of amla in preventing oxidative stress-induced cell damage and protein alterations. Red blood cells (RBCs) were preincubated with different concentrations of amla extract (50, 100, 150, and 200 μg/mL) and then treated with physiological (5 mM) and pathological (50 mM) concentrations of glucose for 24 h. In another in vitro study, the plasma was pretreated with different concentrations of amla extract and then incubated with two, 2′-Azo-Bis (2-methylpropionamidine) dihydrochloride (AAPH) for two hours.
Malondialdehyde (MDA) levels were decreased, while glutathione levels were significantly increased in RBCs treated with the higher concentrations of amla. In addition to the antioxidant activity observed, treatment with amla restored cell membrane integrity, compared to the control cells.
This randomized, placebo-controlled study aimed to evaluate the health benefits and safety of Amla in healthy subjects, using biomarkers of vascular function, blood hematology, oxidative stress, inflammatory biomarkers, glucose, and lipid profiles, as well as assessments for hepatotoxicity. Participants were randomized to receive 500 mg per day of either placebo or Amla for 18 weeks, during which, they were monitored for the various biomarker endpoints.
The results show that amla supplementation was associated with improvements in blood fluidity, lowering the von Willebrand factor (vWF), reduced markers of oxidative stress, and improved HDL-cholesterol levels, with a concomitant reduction in LDL-cholesterol levels. No biomarkers of hepatotoxicity were observed in relation to amla consumption. These results, not only show the safety of amla as a supplement but also show that it promotes endothelial function and reduces oxidative stress in humans.
The antioxidant effect of amla in skin health was evaluated in this randomized, double-blind, placebo-controlled clinical trial. Female subjects were randomized into one of three groups: group one – lingonberry (25 mg) and amla (30 mg) extract; group two – lingonberry (50 mg) and amla (60 mg) extract; group three – placebo, daily for 12 weeks. Participants were assessed for skin elasticity, thickness, water content, and the degree of wrinkles around the eyes.
After 12 weeks of supplementation, the researchers noted a significant, dose-dependent improvement in skin elasticity, thickness, stratum corneum water content, and the degree of wrinkles around the eyes. This antioxidant effect has expected anti-aging effects on skin health.